| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BBRC.2010.08.112 |
| P953 | full work available at URL | https://api.elsevier.com/content/article/PII:S0006291X10016335?httpAccept=text/xml |
| https://api.elsevier.com/content/article/PII:S0006291X10016335?httpAccept=text/plain | ||
| P698 | PubMed publication ID | 20828536 |
| P2093 | author name string | Chikao Morimoto | |
| Kei Ohnuma | |||
| Ryo Hatano | |||
| Yuko Endo | |||
| Nam H. Dang | |||
| Wataru Takasawa | |||
| P2860 | cites work | Caveolin-1 triggers T-cell activation via CD26 in association with CARMA1 | Q24296240 |
| CD26, let it cut or cut it down. | Q33702158 | ||
| CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO. | Q33947051 | ||
| Diabetes and atherosclerosis: epidemiology, pathophysiology, and management | Q34646074 | ||
| The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity | Q36306512 | ||
| Role of CD26/dipeptidyl peptidase IV in human T cell activation and function | Q36992436 | ||
| Inflammation and immunity in diabetic vascular complications | Q37260195 | ||
| Inflammatory cytokines in vascular dysfunction and vascular disease | Q37315106 | ||
| CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1. | Q37557487 | ||
| CD26: a surface protease involved in T-cell activation | Q39005893 | ||
| Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. | Q39990285 | ||
| Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition | Q40002539 | ||
| Anti-CD26 monoclonal antibody-mediated G1-S arrest of human renal clear cell carcinoma Caki-2 is associated with retinoblastoma substrate dephosphorylation, cyclin-dependent kinase 2 reduction, p27(kip1) enhancement, and disruption of binding to the | Q40272609 | ||
| Prevention and treatment of the complications of diabetes mellitus | Q40496478 | ||
| The structure and function of CD26 in the T-cell immune response | Q41745087 | ||
| Critical role of dipeptidyl peptidase IV in neuropeptide Y-mediated endothelial cell migration in response to wounding | Q43564987 | ||
| Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor | Q44079524 | ||
| Hematopoietic stimulation by a dipeptidyl peptidase inhibitor reveals a novel regulatory mechanism and therapeutic treatment for blood cell deficiencies | Q47924495 | ||
| FcR-mediated crosslinking of Ta1 (CDw26) induces human T lymphocyte activation. | Q54745087 | ||
| Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro | Q67665202 | ||
| Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis | Q71905988 | ||
| Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice | Q78952077 | ||
| Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials | Q94680556 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| inflammation | Q101991 | ||
| P304 | page(s) | 7-12 | |
| P577 | publication date | 2010-09-07 | |
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines | |
| P478 | volume | 401 |
| Q40652421 | Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways |
| Q93187889 | Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism |
| Q38340187 | Antidiabetic therapy in post kidney transplantation diabetes mellitus. |
| Q37888004 | Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. |
| Q34383575 | Cardiovascular impact of drugs used in the treatment of diabetes |
| Q50941572 | Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. |
| Q51572627 | DPP-4 inhibition has beneficial effects on the heart after myocardial infarction. |
| Q38413395 | DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. |
| Q39103371 | Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. |
| Q42175983 | Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis? |
| Q44143356 | Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials |
| Q39237033 | GLP-1-dependent and independent effects and molecular mechanisms of a dipeptidyl peptidase 4 inhibitor in vascular endothelial cells. |
| Q38207948 | GLP-1R activation for the treatment of stroke: updating and future perspectives |
| Q35487986 | Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease |
| Q54583647 | High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV. |
| Q40248047 | Linagliptin attenuates diabetes-induced cerebral pathological neovascularization in a blood glucose-independent manner: Potential role of ET-1. |
| Q36064392 | Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes. |
| Q38213703 | Linagliptin: from bench to bedside |
| Q35654597 | Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients |
| Q38200923 | Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate |
| Q51444618 | Possible new therapeutic agents for malignant pleural mesothelioma: anti-CD26 monoclonal antibody and naftopidil. |
| Q97885840 | Pro-Angiogenic and Pro-Inflammatory Regulation by lncRNA MCM3AP-AS1-Mediated Upregulation of DPP4 in Clear Cell Renal Cell Carcinoma |
| Q38042110 | Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease |
| Q38134116 | Targeting inflammation in the treatment of type 2 diabetes |
| Q42801660 | Teneligliptin, a dipeptidyl peptidase-4 inhibitor, attenuated pro-inflammatory phenotype of perivascular adipose tissue and inhibited atherogenesis in normoglycemic apolipoprotein-E-deficient mice |
| Q38104293 | The emerging role of dipeptidyl peptidase-4 inhibitors in cardiovascular protection: current position and perspectives |
| Q35148980 | Transcriptome analysis of the hippocampus in novel rat model of febrile seizures |
| Q54573640 | Upregulation of CD26 expression in epithelial cells and stromal cells during wound-induced skin tumour formation. |
| Q41972438 | Vildagliptin stimulates endothelial cell network formation and ischemia-induced revascularization via an endothelial nitric-oxide synthase-dependent mechanism. |
Search more.